Description

Aptose Biosciences Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to discovering and advancing personalized therapeutic solutions to address critical unmet medical needs within the field of oncology, primarily focusing on the United States market. Its active clinical pipeline features several promising candidates. APTO-253 is currently undergoing Phase 1a/b clinical evaluation for patients battling relapsed or treatment-resistant blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS). Another compound, HM43239, is progressing through Phase 1/2 clinical trials, specifically targeting individuals with relapsed or refractory AML. Furthermore, luxeptinib is in Phase 1a/b clinical testing, designed to treat patients suffering from recurring or treatment-resistant B-cell malignancies—such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas—as well as AML and HR MDS. Aptose also has APL-581 under development, a program centered on a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor. The company has established strategic agreements with CrystalGenomics, Inc. and OHM Oncology. Incorporated in 1986, Aptose Biosciences Inc. previously operated as Lorus Therapeutics Inc. before adopting its current name in August 2014. Its corporate headquarters are located in Toronto, Canada.